Skip to main content

Table 2 Base case results

From: Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

  Ceritinib (450 mg) Crizotinib Ceritinib vs. Crizotinib
Cost (USD)
 Drug and drug administration costs, initial treatment 82,215 82,623 − 408
 Drug and drug administration costs, post-progression treatment 10,392 9,921 471
 Treatment associated adverse event costs 1,982 1,197 785
 Medical costs 62,992 56,683 6,309
 Total costs 157,581 150,424 7,157
Effectiveness
 Total QALYs 3.22 2.68 0.54
 Total LYs 4.51 3.85 0.66
Incremental cost-effectiveness ratio (ICER) (USD)
 Incremental cost per QALY gained    13,343
 Incremental cost per LY gained    10,794
  1. ICER, incremental cost-effectiveness ratio; LY, Life-year; mg, milligram; QALY, quality-adjusted life year; USD, United States Dollar